MEMY » Topics » PDE10 Inhibitor Program

These excerpts taken from the MEMY 10-K filed Mar 28, 2008.
PDE10 Inhibitor Program
 
PDE10 is an enzyme that has been shown to be present at high levels in neurons in areas of the brain that are closely associated with many neurological and psychiatric disorders. PDE10 degrades the intracellular signaling molecules cAMP and cGMP, molecules that are responsible for improving the function of many different cells in the body, including neurons. By inhibiting PDE10, levels of cAMP and cGMP are increased within neurons and the ability of these neurons to function properly is thereby improved. We believe that PDE10 inhibitors may be useful in treating a range of neurological and psychiatric disorders.
 
Under our collaboration agreement with Amgen for the development of PDE10 inhibitors, which we refer to as our 2005 Amgen PDE10 Inhibitor Agreement, Amgen has an exclusive license to our PDE10 inhibitors.
 
PDE10
Inhibitor Program



 



PDE10 is an enzyme that has been shown to be present at high
levels in neurons in areas of the brain that are closely
associated with many neurological and psychiatric disorders.
PDE10 degrades the intracellular signaling molecules cAMP and
cGMP, molecules that are responsible for improving the function
of many different cells in the body, including neurons. By
inhibiting PDE10, levels of cAMP and cGMP are increased within
neurons and the ability of these neurons to function properly is
thereby improved. We believe that PDE10 inhibitors may be useful
in treating a range of neurological and psychiatric disorders.


 



Under our collaboration agreement with Amgen for the development
of PDE10 inhibitors, which we refer to as our 2005 Amgen PDE10
Inhibitor Agreement, Amgen has an exclusive license to our PDE10
inhibitors.


 




This excerpt taken from the MEMY 10-K filed Apr 2, 2007.

PDE10 Inhibitor Program

PDE10 is an enzyme that has been shown to be present at high levels in neurons in areas of the brain that are closely associated with many neurological and psychiatric disorders. PDE10 degrades the intracellular signaling molecules cAMP and cGMP, molecules that are responsible for improving the function of many different cells in the body, including neurons. By inhibiting PDE10, levels of cAMP and cGMP are increased within neurons and the ability of these neurons to function properly is thereby improved. We believe that PDE10 inhibitors may be useful in treating a range of neurological and psychiatric disorders.

Under our 2005 Amgen Agreement, Amgen has an exclusive license to any PDE10 inhibitors that we develop.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki